AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Portfolio Pulse from
AEON Biopharma, Inc. has received a notice of non-compliance from NYSE American due to not meeting stockholders' equity requirements, with a deficit of $32.1 million and losses in two of the last three fiscal years.
February 07, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AEON Biopharma has been notified by NYSE American for non-compliance with listing standards due to a stockholders' equity deficit and consecutive fiscal losses.
The non-compliance notice from NYSE American indicates financial instability, which is likely to negatively impact investor confidence and put downward pressure on AEON's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100